PRESS RELEASE published on 02/19/2026 at 07:17, 6 months 11 days ago BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine BioVersys and partners demonstrate promising results with AlpE in Phase 2a tuberculosis trial, published in New England Journal of Medicine. AlpE shows potential in treating drug-resistant tuberculosis Clinical Trial Drug Resistance BioVersys Tuberculosis AlpE
BRIEF published on 12/11/2025 at 07:05, 8 months 22 days ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
BRIEF published on 12/11/2025 at 07:05, 8 months 22 days ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
PRESS RELEASE published on 12/11/2025 at 07:00, 8 months 22 days ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 9 months 22 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
BRIEF published on 11/10/2025 at 07:05, 9 months 22 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
PRESS RELEASE published on 11/10/2025 at 07:00, 9 months 22 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 9 months 26 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 9 months 26 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 9 months 26 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
Published on 09/02/2026 at 13:00, 56 minutes ago Snipp-Powered Loyalty Programs Earn Two Gold Awards at Loyalty360 Awards
Published on 09/02/2026 at 13:00, 56 minutes ago Eagle Plains and Earthwise Intersect Gold Mineralization in all Holes at the Iron Range Precious Metals Project, SE BC
Published on 09/02/2026 at 13:00, 56 minutes ago Earthwise and Eagle Plains Intersect Gold Mineralization in all Holes at the Iron Range Precious Metals Project, SE BC
Published on 09/02/2026 at 13:00, 56 minutes ago Aztec Drills 83.8 meters of 1.31 g/t AuEq (0.90 g/t Au and 22.61 g/t Ag), Including 7.6 meters of 8.34 g/t AuEq (6.97 g/t Au & 75.42 g/t Ag); Extends the Strike Length by 255 Meters to over 1,250 Meters of Oxide Gold-Silver Mineralization at the Tombstone
Published on 09/02/2026 at 13:00, 56 minutes ago Nebius to participate in upcoming investor conferences
Published on 09/02/2026 at 12:30, 1 hour 26 minutes ago Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Published on 09/02/2026 at 11:42, 2 hours 14 minutes ago Prof. Dr. Michael A. Rübhausen Joins the Medical Advisory Board of Viromed Medical AG
Published on 09/02/2026 at 11:30, 2 hours 26 minutes ago Tolochenaz accueille un nouveau carport photovoltaïque d'envergure réalisé par Romande Energie
Published on 09/02/2026 at 11:05, 2 hours 51 minutes ago Industry Leaders Outline the Future of Energy Independence for European Business in The Economist Panel Ahead of IFA 2026
Published on 09/02/2026 at 11:09, 2 hours 47 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 09/02/2026 at 07:43, 6 hours 13 minutes ago Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 6 hours 13 minutes ago Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 18 hours 56 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 18 hours 56 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
